Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

Fig. 4

Characterization of PTEN null clones reveals these cells closely phenocopy cells with H1047R mutation. A Combinatorial drug screen using lapatinib (blue), AKT inhibitor GSK690693 (red), or equimolar combination of both drugs (green) shows that knockout of PTEN makes cells less sensitive to lapatinib treatment, similar to H1047R knockin cells. B Whole cell lysates collected after 48 h of exposure to 500 nM lapatinib or vehicle were separated by gel electrophoresis and analyzed for the indicated proteins. C Cells were treated with 500 nM lapatinib for a timecourse of 72 h. Whole cell lysates were collected at the indicated times and separated by gel electrophoresis and analyzed for the indicated proteins

Back to article page